WO2007085815A3 - Ligands that bind il-4 and/or il-13 - Google Patents
Ligands that bind il-4 and/or il-13 Download PDFInfo
- Publication number
- WO2007085815A3 WO2007085815A3 PCT/GB2007/000228 GB2007000228W WO2007085815A3 WO 2007085815 A3 WO2007085815 A3 WO 2007085815A3 GB 2007000228 W GB2007000228 W GB 2007000228W WO 2007085815 A3 WO2007085815 A3 WO 2007085815A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligands
- bind
- interleukin
- disclosed
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0710572-0A BRPI0710572A2 (en) | 2006-01-24 | 2007-01-24 | binder, use of binder, methods for treating an allergic, asthma and cancer disease, inhibiting a th2-type immune response, and administering anti-il-4 and anti-il-13 treatment, Pharmaceutical, Drug Dispensing Device, Isolated or Recombinant Nucleic Acid, Vector, Host Cell, Methods for Producing a Binder and Inhibiting Cell Proliferation |
CA002636854A CA2636854A1 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind il-4 and/or il-13 |
JP2008551864A JP2009523460A (en) | 2006-01-24 | 2007-01-24 | Ligand binding to IL-4 and / or IL-13 |
EP07705003A EP1976882A2 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind il-4 and/or il-13 |
AU2007209202A AU2007209202A1 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind IL-4 and/or IL-13 |
US12/223,005 US20110159003A1 (en) | 2006-01-24 | 2007-01-24 | Ligands That Bind Il-4 and/or Il-13 |
EA200801515A EA200801515A1 (en) | 2006-01-24 | 2007-01-24 | LIGANDS THAT BIND IL-4 AND / OR IL-13 |
US12/152,903 US20090060916A1 (en) | 2006-01-24 | 2008-05-15 | Ligands that bind IL-4 and/or IL-13 |
IL192572A IL192572A0 (en) | 2006-01-24 | 2008-07-02 | Ligands that bind il-4 and/or il-13 |
NO20082942A NO20082942L (en) | 2006-01-24 | 2008-07-02 | Ligands that bind IL-4 and / or IL-13 |
US12/992,718 US20120093830A1 (en) | 2006-01-24 | 2009-05-13 | Single domain antibodies that bind il-13 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76170806P | 2006-01-24 | 2006-01-24 | |
US60/761,708 | 2006-01-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/152,903 Continuation-In-Part US20090060916A1 (en) | 2006-01-24 | 2008-05-15 | Ligands that bind IL-4 and/or IL-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007085815A2 WO2007085815A2 (en) | 2007-08-02 |
WO2007085815A3 true WO2007085815A3 (en) | 2007-11-15 |
WO2007085815A8 WO2007085815A8 (en) | 2008-07-31 |
Family
ID=38028503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/000228 WO2007085815A2 (en) | 2006-01-24 | 2007-01-24 | Ligands that bind il-4 and/or il-13 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20110159003A1 (en) |
EP (1) | EP1976882A2 (en) |
JP (2) | JP2009523460A (en) |
KR (1) | KR20080098382A (en) |
CN (1) | CN101578298A (en) |
AU (1) | AU2007209202A1 (en) |
BR (1) | BRPI0710572A2 (en) |
CA (1) | CA2636854A1 (en) |
CR (1) | CR10179A (en) |
EA (1) | EA200801515A1 (en) |
IL (1) | IL192572A0 (en) |
MA (1) | MA30175B1 (en) |
NO (1) | NO20082942L (en) |
TW (2) | TW200740843A (en) |
WO (1) | WO2007085815A2 (en) |
ZA (1) | ZA200806202B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8388965B2 (en) | 2007-10-15 | 2013-03-05 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
WO2009138413A1 (en) * | 2008-05-15 | 2009-11-19 | Domantis Limited | Single domain antibodies that bind il-13 |
JP2009536527A (en) * | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | Binding polypeptide with optimized scaffold |
AU2007358569B2 (en) * | 2007-09-07 | 2014-09-04 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
EP2036980A1 (en) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Down regulation of gene expression using virus-like particles charged with nucleic acid |
AU2017201008B2 (en) * | 2007-10-15 | 2018-12-13 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
AU2008334605B2 (en) * | 2007-12-13 | 2013-07-18 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
WO2009089295A2 (en) * | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
CN112481367A (en) * | 2008-03-31 | 2021-03-12 | 健泰科生物技术公司 | Compositions and methods for treating and diagnosing asthma |
US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
EP2356149A2 (en) * | 2008-10-21 | 2011-08-17 | Domantis Limited | Ligands that have binding specificity for dc-sign |
US8278419B2 (en) | 2008-10-31 | 2012-10-02 | Centocor Ortho Biotech Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
KR20110092328A (en) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ligands that bind il-13 |
AU2009324354B2 (en) | 2008-12-10 | 2016-04-14 | Ablynx Nv | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
SG176203A1 (en) * | 2009-05-28 | 2011-12-29 | Glaxo Group Ltd | Il-13 binding protein |
ES2729422T3 (en) | 2009-05-28 | 2019-11-04 | Glaxo Group Ltd | Antigen binding proteins |
CA2768462A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Ltd. | Improved anti-serum albumin binding single variable domains |
BR112012001977A2 (en) * | 2009-07-29 | 2017-01-31 | Glaxo Group Ltd | immunoglobulin single variable domain, isolated polypeptide, binder, fusion protein, isolated nucleic acid, isolated nucleic acid molecule, vector, host cell, methods for making a polypeptide and for treating and / or preventing a condition, pharmaceutical composition, use of a single variable domain, and pulmonary dispensing device. |
EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
PL2533761T3 (en) * | 2010-02-11 | 2019-09-30 | Ablynx N.V. | Methods and compositions for the preparation of aerosols |
BR112012027863B1 (en) | 2010-04-30 | 2023-03-07 | Janssen Biotech, Inc | POLYPEPTIDES, PROTEIN SCRABOWS, LIBRARIES AND METHODS OF CONSTRUCTION THEREOF, METHOD FOR GENERATING A PROTEIN SCRAPE BINDING TO A SPECIFIC TARGET WITH A PREDEFINED BINDING AFFINITY, ISOLATED NUCLEIC ACID MOLECULES, VECTORS, HOST CELLS, MEDICAL COMPOSITIONS, DEVICES AND MANUFACTURING ARTICLES |
JP6062375B2 (en) | 2011-01-06 | 2017-01-18 | グラクソ グループ リミテッドGlaxo Group Limited | Ligand binding to TGF-beta receptor II |
AR085911A1 (en) | 2011-03-16 | 2013-11-06 | Sanofi Sa | SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
MY165090A (en) | 2011-04-21 | 2018-02-28 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40 |
KR102142385B1 (en) | 2011-09-27 | 2020-08-10 | 얀센 바이오테크 인코포레이티드 | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
PE20150643A1 (en) | 2012-06-22 | 2015-05-29 | Cytomx Therapeutics Inc | ANTI-JAGGED 1 / JAGGED 2 CROSS-REACTIVE ANTIBODIES ACTIVABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE OF THEM |
PT3470432T (en) | 2012-08-21 | 2021-12-14 | Regeneron Pharma | Methods for treating or preventing asthma by administering an il-4r antagonist |
CN113234142B (en) * | 2012-08-22 | 2024-03-05 | 财团法人牧岩生命工学研究所 | Screening and reconstruction method of hyperstable immunoglobulin variable domain and application thereof |
CN106068125B (en) * | 2013-12-17 | 2021-08-31 | Mhs克尔创新有限责任公司 | Compositions and methods for treating adipose tissue accumulation |
US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
KR102368450B1 (en) * | 2014-02-21 | 2022-02-28 | 사노피 바이오테크놀로지 | Methods for treating or preventing asthma by administering an il-4r antagonist |
US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
MX2016013372A (en) | 2014-04-11 | 2017-01-26 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists. |
AU2015329936A1 (en) | 2014-10-10 | 2017-04-20 | Ablynx N.V. | Methods of treating RSV infections |
KR102364212B1 (en) | 2014-10-10 | 2022-02-17 | 아블린쓰 엔.브이. | Inhalation device for use in aerosol therapy of respiratory diseases |
EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
WO2016097313A1 (en) | 2014-12-19 | 2016-06-23 | Ablynx N.V. | Cysteine linked nanobody dimers |
CN109311968A (en) | 2016-05-02 | 2019-02-05 | 埃博灵克斯股份有限公司 | Treat rsv infection |
JP6293829B2 (en) * | 2016-08-05 | 2018-03-14 | モガム インスティチュート フォー バイオメディカル リサーチMOGAM Institute for Biomedical Research | Stabilized immunoglobulin variable domain selection method and application of selected domains |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
BR112019012154A2 (en) | 2016-12-14 | 2019-11-12 | Janssen Biotech Inc | cd8a-binding fibronectin type iii domains |
EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
CN111526920A (en) | 2017-10-30 | 2020-08-11 | 赛诺菲生物技术公司 | Methods of treating or preventing asthma by administering IL-4R antagonists |
CN108855003B (en) * | 2018-06-28 | 2021-01-05 | 南开大学 | Immunoadsorbent for removing inflammatory factors in blood and preparation method thereof |
CN111494625B (en) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | Pharmaceutical compositions for the treatment of IL-4 and/or IL-13 mediated signal transduction related disorders |
WO2020176815A2 (en) * | 2019-02-27 | 2020-09-03 | Zhejiang Nanomab Technology Center Co. Ltd. | Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution |
EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
EP4144758A4 (en) | 2020-04-22 | 2024-05-15 | Mabwell Shanghai Bioscience Co Ltd | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
IL297950A (en) * | 2020-05-06 | 2023-01-01 | Dragonfly Therapeutics Inc | Antibodies targeting clec12a and use thereof |
US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2024038112A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770403A (en) * | 1992-02-19 | 1998-06-23 | Schering Corporation | Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4 |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
WO2004058821A2 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
GB2403952A (en) * | 2003-07-15 | 2005-01-19 | Cambridge Antibody Tech | IL-13 binding molecules |
WO2005062967A2 (en) * | 2003-12-23 | 2005-07-14 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
WO2005121177A2 (en) * | 2004-06-09 | 2005-12-22 | Wyeth | Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them |
WO2006003407A2 (en) * | 2004-07-01 | 2006-01-12 | Glaxo Group Limited | Chimeric and humanised monoclonal antibodies against inteleukin- 13 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
CA2554596A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypetides and therapeutic uses thereof |
WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
-
2007
- 2007-01-24 WO PCT/GB2007/000228 patent/WO2007085815A2/en active Application Filing
- 2007-01-24 BR BRPI0710572-0A patent/BRPI0710572A2/en not_active IP Right Cessation
- 2007-01-24 JP JP2008551864A patent/JP2009523460A/en active Pending
- 2007-01-24 CA CA002636854A patent/CA2636854A1/en not_active Abandoned
- 2007-01-24 TW TW096102774A patent/TW200740843A/en unknown
- 2007-01-24 CN CNA2007800097556A patent/CN101578298A/en active Pending
- 2007-01-24 AU AU2007209202A patent/AU2007209202A1/en not_active Abandoned
- 2007-01-24 JP JP2008551863A patent/JP2009523459A/en active Pending
- 2007-01-24 EA EA200801515A patent/EA200801515A1/en unknown
- 2007-01-24 EP EP07705003A patent/EP1976882A2/en not_active Withdrawn
- 2007-01-24 KR KR1020087020811A patent/KR20080098382A/en not_active Application Discontinuation
- 2007-01-24 TW TW096102778A patent/TW200804593A/en unknown
- 2007-01-24 US US12/223,005 patent/US20110159003A1/en not_active Abandoned
-
2008
- 2008-05-15 US US12/152,903 patent/US20090060916A1/en not_active Abandoned
- 2008-07-02 IL IL192572A patent/IL192572A0/en unknown
- 2008-07-02 NO NO20082942A patent/NO20082942L/en not_active Application Discontinuation
- 2008-07-16 ZA ZA200806202A patent/ZA200806202B/en unknown
- 2008-07-24 CR CR10179A patent/CR10179A/en unknown
- 2008-07-25 MA MA31143A patent/MA30175B1/en unknown
-
2009
- 2009-05-13 US US12/992,718 patent/US20120093830A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770403A (en) * | 1992-02-19 | 1998-06-23 | Schering Corporation | Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4 |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
WO2004058821A2 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
GB2403952A (en) * | 2003-07-15 | 2005-01-19 | Cambridge Antibody Tech | IL-13 binding molecules |
WO2005062967A2 (en) * | 2003-12-23 | 2005-07-14 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
WO2005121177A2 (en) * | 2004-06-09 | 2005-12-22 | Wyeth | Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them |
WO2006003407A2 (en) * | 2004-07-01 | 2006-01-12 | Glaxo Group Limited | Chimeric and humanised monoclonal antibodies against inteleukin- 13 |
Non-Patent Citations (5)
Title |
---|
DOMANTIS: "DOMANTIS' DUAL TARGETING DOMAIN ANTIBODIES SHOWN TO KILL MULTIPLE MYELOMA CELLS AND SPARE HEALTHY CELLS", 7 December 2005, XP002428485 * |
DOMANTIS: "Fact sheet- Company overview", 27 August 2005, XP002434537 * |
HART T K ET AL: "Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 130, no. 1, October 2002 (2002-10-01), pages 93 - 100, XP002434532, ISSN: 0009-9104 * |
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 * |
WAYBACKMACHINE: "History of Domantis web-site: Access: Aug 27 2005", 21 May 2007, XP002434538 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8388965B2 (en) | 2007-10-15 | 2013-03-05 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
KR101681909B1 (en) | 2007-10-15 | 2016-12-05 | 사노피 | Antibodies that bind IL-4 and/or IL-13 and their uses |
KR101682373B1 (en) | 2007-10-15 | 2016-12-06 | 사노피 | Antibodies that bind IL-4 and/or IL-13 and their uses |
Also Published As
Publication number | Publication date |
---|---|
TW200740843A (en) | 2007-11-01 |
TW200804593A (en) | 2008-01-16 |
US20090060916A1 (en) | 2009-03-05 |
IL192572A0 (en) | 2009-02-11 |
WO2007085815A2 (en) | 2007-08-02 |
EA200801515A1 (en) | 2009-02-27 |
JP2009523459A (en) | 2009-06-25 |
US20110159003A1 (en) | 2011-06-30 |
MA30175B1 (en) | 2009-01-02 |
NO20082942L (en) | 2008-10-15 |
CN101578298A (en) | 2009-11-11 |
EP1976882A2 (en) | 2008-10-08 |
CA2636854A1 (en) | 2007-08-02 |
JP2009523460A (en) | 2009-06-25 |
ZA200806202B (en) | 2009-11-25 |
KR20080098382A (en) | 2008-11-07 |
US20120093830A1 (en) | 2012-04-19 |
BRPI0710572A2 (en) | 2013-01-08 |
CR10179A (en) | 2008-10-29 |
WO2007085815A8 (en) | 2008-07-31 |
AU2007209202A1 (en) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007085815A8 (en) | Ligands that bind il-4 and/or il-13 | |
WO2006003388A8 (en) | Compositions and methods for treating inflammatory disorders | |
WO2007024715A3 (en) | Dual variable domain immunoglobin and uses thereof | |
WO2005118644A3 (en) | Binding molecules capable of neutralizing rabies virus and uses thereof | |
WO2008024188A3 (en) | Dual variable domain immunoglobulin and uses thereof | |
WO2005112977A3 (en) | Compositions for treatment with glucagon-like peptide, and methods of making and using the same | |
WO2008123999A3 (en) | Anti-ige antibodies | |
WO2007143098A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
WO2007143090A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
EP1753498A4 (en) | Filter media and methods of manufacture | |
HRP20130460T1 (en) | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd | |
WO2007079218A3 (en) | Metalloproteinase binding proteins | |
WO2007082068A3 (en) | Methods and compositions for treating asthma in human and non human primates | |
HK1175117A1 (en) | Composition and method for the treatment of asthma symptoms | |
MX2011005541A (en) | Ligands that bind il-13. | |
EP2500359A3 (en) | Dual variable domain immunoglobulin and uses thereof | |
EP1627046A4 (en) | Domain-exchanged binding molecules, methods of use and methods of production | |
PL1919951T3 (en) | Anti-tnf-alpha antibodies and methods of use | |
WO2008048685A3 (en) | Ox40 aptamers | |
WO2007007327A3 (en) | Il-32 modulators | |
WO2006066110A3 (en) | Cav2 RELATED COMPOSITIONS AND METHODS | |
SI2314621T1 (en) | Binding molecules capable of neutralizing rabies virus and uses thereof | |
MX350222B (en) | Dual variable domain immunoglobin and uses thereof. | |
GB0506612D0 (en) | Methods and compositions to treat asthma | |
GB0506299D0 (en) | Methods and compositions to treat asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780009755.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 192572 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569644 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801515 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2636854 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2890/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007705003 Country of ref document: EP Ref document number: 2007209202 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008071217 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551864 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/009528 Country of ref document: MX Ref document number: 12008501719 Country of ref document: PH Ref document number: CR2008-010179 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08084206 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2007209202 Country of ref document: AU Date of ref document: 20070124 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2007209202 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087020811 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0710572 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080724 |